FinTrust Capital Advisors’s West Pharmaceutical WST Stock Holding History

FinTrust Capital Advisors’s Portfolio WST Stock Details WST Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-28	Closed	-$7K	–	1294
2022 Q3	$7K	Buy	28 +5	+22%	+$1.52K	﹤0.01%	975
2022 Q2	$7K	Sell	23 -9	-28%	-$2.93K	﹤0.01%	987
2022 Q1	$13K	Hold	32	–	–	﹤0.01%	875
2021 Q4	$15K	Hold	32	–	–	﹤0.01%	831
2021 Q3	$14K	Sell	32 -13	-29%	-$5.48K	﹤0.01%	833
2021 Q2	$16K	Sell	45 -3	-6%	-$991	﹤0.01%	815
2021 Q1	$14K	Hold	48	–	–	﹤0.01%	812
2020 Q4	$14K	Hold	48	–	–	﹤0.01%	765
2020 Q3	$13K	Sell	48 -21	-30%	-$5.56K	﹤0.01%	744
2020 Q2	$16K	Hold	69	–	–	0.01%	669
2020 Q1	$11K	Hold	69	–	–	0.01%	741
2019 Q4	$10K	Hold	69	–	–	﹤0.01%	748
2019 Q3	$10K	Sell	69 -38	-36%	-$5.23K	﹤0.01%	765
2019 Q2	$13K	Hold	107	–	–	0.01%	686
2019 Q1	$12K	Hold	107	–	–	0.01%	736
2018 Q4	$10K	Buy	+107	New	+$11.6K	﹤0.01%	776

Other funds holding WST

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

APG Asset Management Amsterdam, Netherlands $40.7B AUM 39.97% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

FinTrust Capital Advisors's WST Position: Q4 2022 in Review

FinTrust Capital Advisors sold out of West Pharmaceutical (WST) in Q4 2022, closing a stake of 28 shares — an estimated $7K sold.

FinTrust Capital Advisors first reported a position in WST in Q4 2018 and held it in 16 quarters. The position peaked at $16K in Q2 2021. 637 funds tracked by Wall St. Rank hold WST as of Q4 2022.

FinTrust Capital Advisors reported no remaining West Pharmaceutical position as of Q4 2022 after selling out during the quarter.
FinTrust Capital Advisors sold 28 West Pharmaceutical shares in Q4 2022, an estimated $7K.
FinTrust Capital Advisors first reported a position in West Pharmaceutical in Q4 2018 and held it in 16 quarters.
FinTrust Capital Advisors's West Pharmaceutical position peaked at $16K in Q2 2021.
637 funds tracked by Wall St. Rank held West Pharmaceutical as of Q4 2022.

Based on FinTrust Capital Advisors's 13F filing for Q4 2022, filed 14 Feb 2023.